These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 31815838

  • 1. Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study).
    Miura M, Kobayashi T, Igarashi T, Hamada H, Iwata N, Sasaki Y, Matsukawa M, Sato N, Kubo H, Takei S.
    Pediatr Infect Dis J; 2020 Jan; 39(1):41-47. PubMed ID: 31815838
    [Abstract] [Full Text] [Related]

  • 2. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
    Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S, Oonishi T, Hashimoto K, Kobayashi N, Waki K, Suzuki Y, Otsubo Y, Yamada H, Ishikawa C, Kato T, Fuse S.
    Sci Rep; 2018 Jan 31; 8(1):1994. PubMed ID: 29386515
    [Abstract] [Full Text] [Related]

  • 6. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 31; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y, Kim J, Hong YM, Sohn S.
    Pediatr Infect Dis J; 2016 Apr 31; 35(4):457-9. PubMed ID: 26673981
    [Abstract] [Full Text] [Related]

  • 10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Wang L, He M, Wang W, Li S, Zhao G.
    Eur J Pediatr; 2024 Apr 17; 183(4):1765-1776. PubMed ID: 38240765
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
    Koné-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, Meinzer U, Cherqaoui B, Galeotti C, Boukhedouni N, Agostini H, Arditi M, Lambert V, Piedvache C.
    Arthritis Rheumatol; 2021 Jan 17; 73(1):151-161. PubMed ID: 32779863
    [Abstract] [Full Text] [Related]

  • 19. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 20. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
    Ebata R, Yasukawa K, Nagai K, Saito Y, Higashi K, Homma J, Takada N, Takechi F, Saito N, Kobayashi H, Okunushi K, Hamada H, Kohno Y, Hanaoka H, Shimojo N.
    Pediatr Int; 2019 May 11; 61(5):438-443. PubMed ID: 30916859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.